html5-img
1 / 14

Eli Lilly and company Matt Spahlinger ACG 2021-003

Eli Lilly and company Matt Spahlinger ACG 2021-003. Executive Summary.

fabiano
Download Presentation

Eli Lilly and company Matt Spahlinger ACG 2021-003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eli Lilly and company Matt SpahlingerACG 2021-003

  2. Executive Summary Eli Lilly is a strong company with sales increasing yearly. The recession of the pharmaceutical industry caused the stock prices to level off at the end of the 90’s. Although the company is owned mostly by creditors it is a productive corporation that will continue to provide breakthroughs in medicine for years to come. http://www.lilly.com/investor/annual_report/lillyar2005.pdf

  3. Part A. Introduction(dollars in millions) • CEO: Sidney Taurel • Administrative headquarters: Indianapolis,Ind • Latest fiscal year ended Dec 31, 2005. • Eli Lilly is a pharmaceutical company that is leading the field in research and development of new medicines. • United States 2005 7,798.1$ in sales Europe, Middle East, and Africa 2005 1,563.1$ in sales other foreign countries 2005 1740.7$ in sales

  4. Part A. Audit Report • Eli Lilly’s independent auditors are Ernst and Young. • The auditors of Ernst and Young agree that all of the information provided in the financial statements are accurate representations of the financial happenings of Ely Lilly and Company for the 2005 fiscal year

  5. Part A. Stock Market Information • As of Oct 9, 2006 Eli Lilly stock was 57.51$ per share. • Over the past twelve months, the price of stock has been as high as 59.24$ per share and as low as 49.47$ per share. • Dividends paid on 9/08/2006 were .400$ per share • As of 10/9/2006 • Upon looking at the stock trends for the last ten years, Eli Lilly and Company is not at it’s peak price per share, however the price has been quite stable for the last 5 years with the highest stock prices occurring at the end of winter. I would recommend holding your shares until the beginning of February and then selling when the shares have reached their peak price.

  6. Part B. Industry Situation and Company Plans The pharmaceutical industry is facing many problems. The rising cost of health care is putting increasing pressure on the federal government to pay for more health care. Starting in January the government will start paying for prescription drugs for 42 million people increasing the current amount of Eli Lilly drugs being paid for by the federal government from 33% to 50%. In addition increased incident's with Vioxx recalls and reports of anti depressants being a cause of suicide have forced the FDA to require manufacturers to increase the amount of warning labels on their packaging. These two factors along with the decreased amounts of drugs that the FDA approves for sale every year are putting increased strain on the industry. Eli Lilly and Company are looking towards the future by staying ahead of the competition and leading the industry in research and development, patenting new drugs and providing innovations in health care.

  7. Part C. Income Statement(dollars in millions) The income statement for Eli Lilly and company is a single step income statement.

  8. Part C. Balance Sheet Note: (Dollars in Millions). The amount in the stockholders equity account changed the most of all of he accounts on the balance sheet

  9. Part C. Statement of Cash Flows(dollars in millions) Cash flows from operations were 1881.1$ more then net income for 2005 and 2350.4$ more then net income in 2004 Eli Lilly and Company has grown from its investments in the past two years however its net income from operations in 2003 was higher then its has been in the last two years and has not yet returned to its peak levels. With its long term investments in diabetes research, company officials hope to boost gains from operations in the near future. Eli Lilly and Company’s primary source of financing is from long term loans for 3000.00$ Other incomes include the selling of stock for 377.9$ Over the past two years cash flow has decreased from 5365.3$ in 2004 to 30063.7$ in 2005

  10. Part D. Accounting Policies Significant accounting policies short term investments/cash:All highly liquid investments are considered to be cash equivalents. revenue recognition: They recognize revenue from sales at the time title of goods passes to the buyer and he buyer assumes risks and rewards of ownership. inventories: All US based inventories are calculated by the last in first out method. All non US based inventories are calculated by the first in first out method. property and equipment: Stated on the basis of cost provisions for depreciation of buildings & equipment are computed generally by the straight line method at rates based on their estimated useful lives. (12-50 years buildings 3-18 years equipment) Note Topics 1)summary of significant accounting policies 2)implementation of new financial accounting pronouncements 3)acquisitions 4)asset impairments, restructuring & other special changes 5)financial instruments and investments 6)borrowings 7)stock plans 8)other assets & other liabilities 9)shareholders equity 10)earnings per share 11)income taxes 12)retirement benefits 13)contingencies 14)other comprehensive income

  11. Part E. Financial AnalysisLiquidity Ratios Liquidity ratios for he past two fiscal years (dollars in millions): • The amount of working capital in 2005 is 10,791.9$, 2004 10,919.9$ • The current ratio of Eli Lilly and company for 2005 is 1.78, 2004 1.782 • The receivable turnover ratio for 2005 is 6.7, for 2004 6.33 • On average, the amount of sales not collected per day in 2005 is 54.4$, 2004 57.6$ • The inventory turnover ratio for 2005 is 1.66, for 2004 1.54 • The average amount of inventor on hand per day for 2005 is 219.8$, for 2004 237$

  12. Part E. Financial AnalysisProfitability Ratios Profitability ratios for the past two fiscal years (dollars in millions): • The profit margin ratio for 2005 is 13.5%, 2004 13% • The asset turnover ratio for 2005 is .629 times, for 2004 .56 times • The return on assets for 2005 is 8.1%, 2004 7% • The return on equity for 2005 is 15%, for 2004 16.6%

  13. Part E. Financial AnalysisSolvency Ratio Debt to equity ratios for the last two years: • 2005- 127% • 2004- 127% • For both years creditors own more then half of the company

  14. Part E. Financial AnalysisMarket Strength Ratios Market strength ratios for the last two years (dollars in millions): • Price /earnings per share 2005 1.82$$ price/earnings per share for 2004 1.67$$ • The dividend yield for 2006 stock prices is .6%, dividend yield for 2005 stock prices is .7%.

More Related